期刊文献+

阿帕替尼联合紫杉醇治疗老年晚期非小细胞肺癌患者的效果 被引量:1

Effects of Apatinib combined with Paclitaxel in treatment of elderly patients with advanced non-small cell lung cancer
下载PDF
导出
摘要 目的:观察阿帕替尼联合紫杉醇治疗老年晚期非小细胞肺癌(NSCLC)患者的效果。方法:回顾性分析2018年3月至2019年4月该院收治的84例老年晚期NSCLC患者的临床资料,按照治疗方法不同将其分为观察组与对照组各42例。对照组采用紫杉醇单药化疗,观察组在对照组基础上联合阿帕替尼治疗,比较两组疾病控制率、不良反应发生率、治疗前后血清肿瘤标志物[癌胚抗原(CEA)、血管内皮生长因子(VEGF)、细胞角蛋白19片段(CYFRA21-1)]水平、中位无疾病进展生存期(PFS)和总生存期(OS)。结果:观察组疾病控制率为71.43%(30/42),高于对照组的47.62%(20/42),差异有统计学意义(P<0.05);两组不良反应发生率比较,差异均无统计学意义(P>0.05);治疗后,观察组血清CEA、VEGF和CYFRA21-1水平均低于对照组,差异有统计学意义(P<0.05);观察组中位PFS和OS均长于对照组,差异有统计学意义(P<0.05)。结论:阿帕替尼联合紫杉醇治疗老年晚期NSCLC患者可提高疾病控制率,降低血清肿瘤标志物指标水平,以及延长生存期,其效果优于单纯紫杉醇治疗。 Objective:To observe effects of Apatinib combined with Paclitaxel in treatment of elderly patients with advanced non-small cell lung cancer(NSCLC).Methods:The clinical data of 84 elderly patients with advanced NSCLC treated in this hospital from March 2018 to April 2019 were retrospectively analyzed,and they were divided into observation group and control group according to different treatment methods,42 cases in each.The control group was treated with Paclitaxel single-agent chemotherapy,while the observation group was treated with Apatinib on the basis of that of the control group.The disease control rate,the incidence of adverse reactions,the serum tumor marker levels[carcinoembryonic antigen(CEA),vascular endothelial growth factor(VEGF)and cytokeratin-19-fragment(CYFRA21-1)],the median progression-free survival(PFS)and the overall survival(OS)were compared between the two groups before and after the treatment.Results:The disease control rate in the observation group was 71.43%(30/42),which was higher than the control group of 47.62%(20/42),and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After the treatment,the serum levels of CEA,VEGF and CYFRA21-1 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).Further,the median PFS and OS of the observation group were longer than those of the control group,and the differences were statistically significant(P<0.05).Conclusions:Apatinib combined with Paclitaxel in the treatment of the elderly patients with advanced NSCLC can improve the disease control rate,reduce the serum tumor marker levels,and prolong the survival period.Moreover,it is superior to single Paclitaxel treatment.
作者 芦明月 LU Mingyue(1^(st) Department of Oncology of Jiamusi Tumor Tuberculosis Hospital,Jiamusi 154007 Heilongjiang,China)
出处 《中国民康医学》 2022年第17期28-31,共4页 Medical Journal of Chinese People’s Health
关键词 阿帕替尼 紫杉醇 非小细胞肺癌 癌胚抗原 不良反应 生存期 Apatinib Paclitaxel Non-small cell lung cancer Carcinoembryonic antigen Adverse reaction Survival period
  • 相关文献

参考文献12

二级参考文献133

共引文献383

同被引文献22

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部